Section 5: Patient Safety and Quality Assurance

5PSQ-055

ANALYSIS OF CHEMOTHERAPY EXTRAVASATION AND ITS MANAGEMENT IN AN OUTPATIENT CLINIC OF A TERTIARY CARE HOSPITAL

5PSQ-053

DRUG UTILISATION STUDY OF HUMAN NORMAL IMMUNOGLOBULIN IN HAEMATOLOGICAL AND ONCOLOGIC PATIENTS IN A TEACHING PAEDIATRIC HOSPITAL

5PSQ-052

OPTIMISATION OF HUMAN NORMAL IMMUNOGLOBULINS IN PAEDIATRIC CANCER: A MULTIDISCIPLINARY TEAMWORK

5PSQ-049

EFFECTIVENESS AND RENAL SAFETY OF TAF/FTC/EVG/ COBI IN REAL CLINICAL PRACTICE

5PSQ-048

DARUNAVIR/COBICISTAT PHARMACOLOGICAL INTERACTIONS: CLINICAL RELEVANCE AND ACTION MECHANISM

5PSQ-046

DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C VIRUS IN HIV CO-INFECTED PATIENTS

5PSQ-045

COST-EFFECTIVENESS ANALYSIS OF ISAVUCONAZOLE VERSUS VORICONAZOLE

5PSQ-042

ACUTE EOSINOPHILIC PNEUMONIA SECONDARY TO DAPTOMYCIN: A CASE REPORT

5PSQ-038

ACTION OF THE PHARMACIST ON THE ADEQUATE PRESCRIPTION OF ANTIBIOTICS

5PSQ-034

ASSESSMENT OF LINEZOLID’S HAEMOTOLOGICAL TOXICITY AND RELATED RISK FACTORS IN CLINICAL PRACTICE

5PSQ-033

HIGH DOSAGE OF TIGECYCLINE IN MULTIDRUGRESISTANT ACINETOBACTER BAUMANNII: USE ANALYSIS DURING AN OUTBREAK

5PSQ-031

PNEUMOCYSTIS CARINII PNEUMONIA PREVENTION IN LUNG TRANSPLANTATION: IS ATOVAQUONE EFFECTIVE?

5PSQ-022

PHARMACOLOGICAL CARDIOVERSION IN PATIENTS WITH RECENT-ONSET ATRIAL FIBRILLATION AT EMERGENCY DEPARTMENT: EFFICACY AND SAFETY OF VERNAKALANT

5PSQ-021

PRESCRIPTION ERRORS ASSOCIATED WITH ONDEMAND MEDICATION RECONCILIATION AT ADMISSION: SUBLINGUAL NITROGLYCERIN AS AN EXAMPLE

5PSQ-017

SAFETY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN TREATMENT OF IRON DEFICIENCY IN CHILDREN UNDER 2 YEARS WITH INTESTINAL FAILURE

Pages